Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: A position statement of the Korean Diabetes Association

on behalf of the Committee of Clinical Practice Guideline of Korean Diabetes Association

Research output: Contribution to journalReview article

20 Scopus citations


In 2017, the Korean Diabetes Association (KDA) published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). The KDA regularly updates its Clinical Practice Guidelines, but since the last update in 2015, many results from clinical trials have been introduced, and domestic data from studies performed in Korean patients with T2DM have been published. Recently, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations. Additionally, new data from clinical trials using dipeptidyl peptidase 4 inhibitors and thiazolidinediones in Korean patients with T2DM were added. Following a systematic review and assessment of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the use of antihyperglycemic agents and revised the treatment algorithm for Korean adult patients with T2DM.

Original languageEnglish
Pages (from-to)337-348
Number of pages12
JournalDiabetes and Metabolism Journal
Issue number5
StatePublished - 1 Oct 2017


  • Diabetes mellitus
  • Hypoglycemic agents
  • Insulin
  • Practice guideline
  • Type 2

Cite this